Elicio Therapeutics, Inc. (ELTX)

US — Healthcare Sector

Peers:

Automate Your Wheel Strategy on ELTX

With Tiblio's Option Bot, you can configure your own wheel strategy including ELTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol ELTX
Rev/Share 0.0
Book/Share 0.6875
PB 11.6648
Debt/Equity 0.6504
CurrentRatio 1.8343
ROIC -2.5757

MktCap 128295940.0
FreeCF/Share -2.9577
PFCF -3.3494
PE -2.0254
Debt/Assets 0.2058
DivYield 0
ROE 8.9005

Rating D+
Score 1
Recommendation Strong Sell
P/E Score 1
DCF Score 1
P/B Score 1
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher

ELTX
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive

Elicio Therapeutics (ELTX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

image for news Here's Why Elicio Therapeutics (ELTX) Could be Great Choice for a Bottom Fisher

Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

ELTX
Published: April 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Here is how Elicio Therapeutics (ELTX) and Inventiva S.A. Sponsored ADR (IVA) have performed compared to their sector so far this year.

image for news Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year?

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

ELTX
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral

BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof.

image for news Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

About Elicio Therapeutics, Inc. (ELTX)

IPO Date 2021-02-05
Website https://elicio.com
Industry Biotechnology
CEO Robert T. Connelly
Employees 32

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.